Assessment Status |
NCPE assessment ongoing |
HTA ID |
22009 |
Drug |
Avacopan |
Brand |
Tavneos® |
Indication |
In combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis or microscopic polyangiitis. |
Rapid review commissioned |
14/02/2022 |
Rapid review completed |
08/03/2022 |
Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of avacopan (Tavneos®) compared with the current standard of care. |
Full pharmacoeconomic assessment commissioned by HSE |
01/04/2022 |
Pre-submission consultation with Applicant |
21/06/2022 |
Full submission received from Applicant |
19/10/2022 |